01—Abstract
Summary
Summary of the 10-Q filed May 4, 2023. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. reported a significant decrease in revenue for the first quarter of 2023 compared to the prior year, driven primarily by a substantial decline in COVID-19 vaccine sales.
Total revenue fell by 69% to $1.86 billiona, with product sales contributing $1.83 billion. This sharp drop reflects the ongoing shift of the COVID-19 market towards an endemic, seasonal model. Despite the revenue decline, the company maintained a strong balance sheet with substantial cash, cash equivalents, and investments totaling over $16 billion.
However, operating activities resulted in a net cash used of $1.23 billionb, largely due to decreases in deferred revenue and accrued liabilities, offset by significant investments in research and development. The company also continued its share repurchase program, spending $526 million in the quarter. Moderna's strategic focus appears to be on diversifying its pipeline beyond COVID-19, with substantial investments in R&D for vaccines and therapeutics across various disease areas, including RSV, influenza, CMV, and cancer.
02—Key points
Key Highlights
- Total revenue for Q1 2023 decreased by 69% to $1.86 billion, primarily due to a 69% decline in product sales to $1.83 billion, reflecting the transition to an endemic COVID-19 market.
- Net income for the quarter was $79 million, a significant decrease from $3.66 billion in Q1 2022.
- Research and Development (R&D) expenses increased by 104% to $1.13 billion, indicating continued investment in pipeline development, particularly in RSV, flu, and CMV vaccines, and the personalized cancer vaccine.
- The company maintained a strong liquidity position with $16.37 billion in cash, cash equivalents, and investments as of March 31, 2023.
- Operating activities resulted in a net cash usage of $1.23 billion, a decrease from the $2.76 billion provided in Q1 2022.
- Moderna repurchased $526 million of its common stock during the quarter, continuing its share repurchase program.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2023, Moderna, Inc. kept $0.04.
- Revenue$1.86B100.0%
- Cost of revenue−$792.0M42.5%
- Gross profit$1.07B57.5%
- Operating costs−$1.44B77.1%
- Operating income−$366.0M19.7%
- Interest, other & tax$445.0M23.9%
- Net income$79.0M4.2%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2023filed May 4, 2023Financial Statements
Q1 FY2023 against Q1 FY2022
| Line item | Q1 FY2023Q1 FY2022 | Change |
|---|---|---|
| Revenue | $1.86B$6.07B | −69.3% |
| Cost of Revenue | $792.00M$1.02B | −22.1% |
| Gross Profit | $1.07B$5.05B | −78.8% |
| R&D Expenses | $1.13B$554.00M | +104.2% |
| Operating Expenses | $2.23B$1.84B | +21.2% |
| Operating Income | -$366.00M$4.23B | −108.7% |
| Net Income | $79.00M$3.66B | −97.8% |
| EPS (Basic) | $0.20$9.09 | −97.8% |
| EPS (Diluted) | $0.19$8.58 | −97.8% |
| Shares Outstanding (Basic) | 386.00M402.00M | −4.0% |
| Shares Outstanding (Diluted) | 405.00M426.00M | −4.9% |
05—Questions
Frequently Asked Questions
Why has Moderna's revenue decreased so significantly in the first quarter of 2023?
Moderna's revenue has decreased significantly primarily due to the ongoing transition of the COVID-19 vaccine market from a pandemic to an endemic, seasonal model. This has resulted in lower sales volumes for their COVID-19 vaccines compared to the peak demand experienced in the prior year. The company anticipates continued revenue decline and increased seasonality in COVID-19 vaccine sales.
How is Moderna diversifying its business beyond COVID-19 vaccines?
Moderna is significantly increasing its investment in research and development across a broad pipeline of vaccines and therapeutics. Key areas of focus include vaccines for Respiratory Syncytial Virus (RSV), seasonal influenza (flu), Cytomegalovirus (CMV), and advancing its individualized neoantigen therapy for cancer in collaboration with Merck. The company is also exploring novel indications like Lyme disease and norovirus, demonstrating a strategic effort to build a diversified portfolio.
What is the company's financial health and outlook given the revenue drop?
Despite the substantial revenue decrease from COVID-19 vaccines, Moderna maintains a strong financial position with over $16 billion in cash, cash equivalents, and investments. However, operating activities consumed $1.23 billion in cash during the quarter. The company's outlook depends on the successful progression of its diverse R&D pipeline and the evolving dynamics of the vaccine and therapeutic markets. Significant R&D spending is expected to continue.
What are the implications of the increased R&D spending?
The substantial increase in R&D spending (104% year-over-year) reflects Moderna's commitment to advancing its pipeline, which includes multiple late-stage clinical programs and early-stage research across various therapeutic areas. This increased investment is crucial for developing next-generation vaccines, novel therapeutics, and expanding into new disease areas. While it impacts short-term profitability, it is a strategic move aimed at long-term growth and diversification.
06—Continue